Diabetes Type 2 Clinical Trials 2022

Diabetes Type 2 studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect diabetes type 2 clinical trial in 2022.

Condition

Location

Distance

Age

Clinical Trials Diabetes Type 2 Clinical Trials 2022

Effectiveness

Safety

Budgeting, Purchasing And Cooking Educational Interventionfor Diabetes Mellitus, Type 2

This study is evaluating whether a culturally-targeted healthy foods budgeting, purchasing, and cooking skills intervention aimed at improving the cardio-metabolic health of American Indians with type 2 diabetes who

Effectiveness

Safety

Goodbelly Firstfor Diabetes Mellitus, Type 2

Researchers at MCW have discovered a new pathway that links the type of bacteria present in the intestines to the severity of heart attacks. This discovery of a relationship between intestinal bacteria, bacterial metabolites, and severity of heart attacks means that for the first time, the investigators may be able to determine a person's probability of having a heart attack via non-conventional risk factors. This may provide opportunities for novel diagnostic tests as well as a potential for therapeutic intervention. The link between gut microbiota and the severity of heart attacks may also lead to novel therapeutic approaches (probiotics, non-absorbable antibiotics) to prevent heart attacks from happening. The studies proposed will test the hypothesis that altered intestinal microbiota are mechanistically linked to the pathogenesis of cardiovascular disease. The investigator's objective is to determine whether inflammatory markers in the blood are decreased and endothelial cell function improved by a probiotic in patients with established coronary artery disease. Furthermore, the investigators wish to elucidate a mechanism by which the gut microbiota regulates serum inflammatory markers. Specific Aim 1 will determine the impact of a probiotic on circulating leptin and TMAO levels, conventional risk factors for cardiovascular disease and diabetes (total cholesterol, LDL cholesterol, oxidized LDL, triglycerides, C-reactive protein, serum amyloid A, fibrinogen and adiponectin, glucose-dependent- insulinotropic polypeptide (GIP), glucagon-like-peptide (GLP-1), glucagon, insulin), and their relationship to the intestinal microbiota (15 representative microbial groups) as non conventional risk factors. Several blood samples will be collected to measure biomarkers. Participants will provide periodic stool samples in order to measure gut bacterial biodiversity. Lastly, endothelial cell function (flow mediated dilation) will be measured in order to assess blood vessel function. Specific Aim 2 will determine the impact of a probiotic on metabolites derived from the intestinal microbiota as candidates for non-conventional risk factors of cardiovascular disease. The relationship between metabolites derived from the intestinal microbiota, endothelial cell function and risk factors for cardiovascular disease identified in Specific Aim 1 will be correlated.

Effectiveness

Safety

ENCOMPASS Interventionfor Chronic Kidney Diseases

This study is evaluating whether a patient navigation program can improve care for patients with chronic diseases.

Effectiveness

Safety

Dulaglutidefor Diabetes Mellitus

The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.

Effectiveness

Safety

Cecelia Health Plus OneTouch Verio Reflect® BGM And OneTouch Reveal® Mobile Appfor Diabetes Mellitus

ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can access online via OneTouch Solutions (Cecelia Health, Fitbit, Noom or Welldoc, each in combination with OneTouch Verio Reflect® blood glucose meter and the OneTouch Reveal® mobile app (or Welldoc app for the Welldoc arm)). ECLIPSE is a large parallel arm digital health study combining advanced blood glucose monitoring solutions with a choice of four different health and wellness applications or services. There are four unique study arms that will run in parallel over one year. The primary (A1c) endpoint for each study arm will be after 6 months and subjects will continue to use the interventions for a full year to generate data on sustained engagement with these products and services, and to collect healthcare utilization and health insurance claims information. Each study arm will differ to some degree in terms of patient baseline demographics (since subjects self-select their own app/intervention) and the experience per arm will be unique, and therefore each study arm will be analysed separately in terms of endpoints and outcomes.

Effectiveness

Safety

Diabetes Self-management Coachingfor Diabetes Mellitus, Type 2

Background: Diabetes mellitus is the third most prevalent chronic disease globally. It is a metabolic disorder characterized by elevated blood glucose because of impaired insulin production, reduced insulin effectiveness, or both. It is a major contributor for physical disability and impaired quality of life. Diabetic Self-Management programs help to control blood glucose, reduce hospitalization, and increase compliance; however, the program is underutilized in the Primary Care settings globally, due to cognitive, financial, behavioral, and emotional factors. Health coaching is a client-centered self-management approach informed by behavioral change theories to empower individuals to identify their strengths and resources and achieve their health and wellness goals. Purpose: The study's overarching goal is to determine whether implementing Diabetes Self-Management (DSM) Coaching program can be effective and feasible for individuals with type diabetes in the Ethiopian primary care context. The study has two aims: Aim 1. To determine the feasibility of implementing the Diabetic Self-Management Coaching Program Aim 2. To evaluate the effectiveness of the Diabetic Self-Management Coaching program. Method: The study will employ a single-blinded feasibility randomized controlled trial followed by a concurrent mixed-method design. A block randomization technique with block size of 4 will be used to allocate eligible participants for the quantitative part. Structured outcome measures will be used to collect data on self-efficacy, self-care practice, and glycated hemoglobin A1c. Qualitative description approach with an in-depth interview method of data collection will be used to explore perspectives of participants, barriers and facilitators, and acceptability of the program. Mean, median and frequencies will be computed. Depending on the normality of the distribution and number of participants t-test, x2 test, sign tests, and ANOVA will be considered to analyze the data. Inductive qualitative content analysis approach will be followed to analyze qualitative data. Qualitative and quantitative data will be merged at result level for further interpretation and presented in discussion section. Significance: The study will be used to determine the feasibility of the Diabetic Self-Management Coaching program in the Ethiopian primary care settings. Study participants will be benefited from the coaching program and will improve their self-efficacy, diabetes self-care practice, and blood glucose level. Furthermore, the study will have a paramount advantage to establish a foundation for future definitive trial that can prove effectiveness of the program.

Effectiveness

Safety

GZR-18for Diabetes Mellitus, Type 2

Single ascending dose first time in human study for GZR18 in healthy subjects

Effectiveness

Safety

Semaglutide 1 Mgfor Diabetes Mellitus, Type 2

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide. Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries. Participants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls. At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Effectiveness

Safety

SomaSignal Informed Medical Management SSCVDfor Diabetes Mellitus

Despite the development of novel treatments, cardiovascular disease (CVD) remains the leading cause of death and disability. It has been observed in clinical practice, that the use of novel glycemia-lowering therapies with cardioprotective features remains profoundly low despite proven efficacy. It has been proposed that such low uptake is more related to insurance type and coverage than to risk assessment. While it can be easy to blame prescribing deficiencies on complacent physicians and/or over-frugal payors, SomaLogic believes there is more likely to be a fundamental problem with the cost and risk-effective allocation of such therapies, which are neither low in cost nor free of adverse events. As current clinical trials and guidelines tend to "bundle" participants together, there is an absence of individualized assessment of residual cardiovascular risk. This leads to physicians, participants, and payors being relatively uninformed as to the need for and/or likely benefits of such therapies in an individual. Simply giving every eligible participant a drug regardless of residual risk would be unaffordable and would create adverse effects and costs for people at low residual risk who might not actually benefit from the drugs. To resolve this lack of precision in risk assessment, SomaLogic has performed the largest ever proteomic program to date with over 36,000 samples from 26,000 participants in eleven clinical studies, for a total of over 180,000,000 protein measurements, to develop and validate a surrogate proteomic endpoint for cardiovascular outcomes. The SomaSignal Cardiovascular Risk (SSCVR) test, a 27-protein model encompassing ten biological systems.

Effectiveness

Safety

Normal Salinefor Diabetes Mellitus

This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.

Effectiveness

Safety

Dapagliflozinfor Diabetes Mellitus

Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels. The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This study will provide novel information regarding the mechanism of effects of novel treatments for endothelial function and vascular health in patients with T2DM to reduce cardiovascular (CV) risk. The research aims to assess the: effects of dapagliflozin on EC phenotype. impact of dapagliflozin on vasodilator function and additional measures of vascular health including arterial stiffness and circulating markers of vascular health.

Effectiveness

Safety

Insulin Detemirfor Diabetes, Gestational

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

Effectiveness

Safety

Case-managementfor Diabetes Mellitus, Type 2

This study is evaluating whether a nutrition program can improve diabetes control in people with diabetes.

Effectiveness

Safety

ELGfor Diabetes Mellitus

This study is evaluating whether a new device can measure blood glucose levels without taking blood samples.

Effectiveness

Safety

Afrezzafor Diabetes, Autoimmune

This study is evaluating whether Afrezza is safe and effective in combination with a basal insulin in pediatric subjects with type 1 or type 2 diabetes mellitus.

Effectiveness

Safety

Zanamivirfor Diabetes Mellitus

This study is evaluating whether a drug that inhibits neuraminidase can improve endothelial function in people with type 2 diabetes.

Effectiveness

Safety

Type 2 Diabetes Appropriate Food Boxes + Diabetes Educationfor Diabetes Mellitus, Type 2

Develop, implement, and evaluate the effectiveness of an intervention to use home-delivery of Type 2 diabetes (T2D)-appropriate food boxes with plain language adapted education materials to improve the nutritional health, physical activity, and health outcomes of low-income food insecure people with T2D in northwest Arkansas.

Effectiveness

Safety

MTMfor Diabetes Mellitus, Type 2

This study is evaluating whether a medically tailored meal program may help improve diabetes management for individuals with food insecurity.

Effectiveness

Safety

Healthy Food Subsidyfor Diabetes Mellitus, Type 2

Multiple Locations, Canada

18+

All Sexes

Recruiting

Multiple Locations, Canada

18+

All Sexes

This study is evaluating whether a subsidized healthy food prescription program can improve blood glucose levels in people with diabetes.

Effectiveness

Safety

Oral Semaglutidefor Diabetes Mellitus, Type 2

This study is evaluating whether a drug may help treat type 2 diabetes.

Effectiveness

Safety

Insulin Icodecfor Diabetes Mellitus, Type 2

This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. The study will last for about 1 ½ years. Participants will have 37 clinic visits and 26 phone calls with the study doctor. At 11 clinic visits participant will have blood samples taken. At 8 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Participants will be asked to wear a sensor that measures the blood sugar all the time in 5 periods of about one month during the study (about 5 months in total). Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Effectiveness

Safety

Family Diabetes Self-Management Education And Supportfor Diabetes Mellitus, Type 2

This study is evaluating whether family involvement in diabetes education sessions will improve outcomes for patients with type 2 diabetes.

Effectiveness

Safety

Ertugliflozin 5 Mgfor Diabetes Mellitus

This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin) alters cardiac metabolism compared to placebo in a single blinded (to subject), randomized, parallel group, active controlled, single center experimental design.

Effectiveness

Safety

Autologous Adipose-derived Mesenchymal Stem/stromal Cells (MSC) Higher Dosefor Diabetes Mellitus, Type 2

This study is evaluating whether stem cells from fat may help treat kidney disease.

Effectiveness

Safety

Tailored Lighting Interventionfor Alzheimer Disease

This study is evaluating whether a lighting intervention may help treat Alzheimer's disease.

Effectiveness

Safety

Peer Led Diabetes Self-Management Supportfor Diabetes Mellitus

The Michigan Men's Diabetes Project 2 (MenD 2) is an 18-month pilot randomized clinical trial. We are looking to recruit 60 Black men with type 2 diabetes (need to have diagnosis for at least 6 months) that are over the age of 21. Interested participants need to be under the care of a physician for their diabetes, have access to reliable transportation for study activities, and be willing to participate in 4 health assessments where they will get their A1C, blood pressure, height, and weight measured and they will complete a survey. All participants will receive 10 hours of diabetes self-management education with a Certified Diabetes Care and Education Specialist. Participants randomized to the intervention arm will also be offered 6 months of monthly diabetes self-management support (DSMS) sessions with trained Peer Leaders who are also Black men with type 2 diabetes. After the 6 months of support, this group will transition into 6 months of ongoing support where they can continue DSMS and/or other diabetes related initiatives that are important to the group and chosen by the group. Due to the COVID-19 pandemic, DSME and DSMS sessions will likely be held via Zoom, ongoing support sessions have potential to be in person. The 4 health assessments will take place at baseline, 3-months, 9-months, and 15-months.

Effectiveness

Safety

IcoSemafor Diabetes Mellitus

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec. Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe. Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.

Effectiveness

Safety

Diabetes Educationfor Diabetes Mellitus

The overarching aim of this proposal is to test the efficacy of financial incentives in improving HbA1c, blood pressure, and quality of life in food insecure adults with poorly controlled type 2 diabetes. Using a clinical trial design, the investigators will randomize food insecure adults with type 2 diabetes to one of three financial incentive structures in combination with monthly mailings that will include diabetes education, healthy recipes, and meal planning resources.

Effectiveness

Safety

Tirzepatide Dose 2for Type2 Diabetes

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both. The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.

Effectiveness

Safety

Exogenous Ketone Monoesterfor Diabetes Mellitus

Ketone bodies are a fuel source and signaling molecule that are produced by the body during prolonged fasting or if an individuals consistently eats a low-carbohydrate "keto" diet. Blood ketones can be used as a source of energy by the body, but they may also act as signals that impact the functioning of different cells in the body. Recently, the availability of ketone supplements that can be taken orally allows for raising blood ketones without having to fast or eat a "keto" diet. The investigators' studies and those of other researchers have shown that ketone supplementation can lower blood sugar without having to make any other dietary changes. Oral ingestion of ketones may therefore be an effective strategy to improve blood sugar control and influence how cells function. The main objective of this study is to determine if consuming a ketone supplement 3 times per day (before meals) for 14 days lowers blood sugar and impacts how the body's cells function. The results of this study will be used to guide future recommendations on the utility of ketone supplements for improving health in individuals with, or at elevated risk of, type 2 diabetes.

Effectiveness

Safety

Noom Mobile Applicationfor Diabetes Mellitus

This study is evaluating whether a smartphone app can help people with type 2 diabetes lose weight.

Effectiveness

Safety

MANUPfor Coping Behavior

Many Black Americans continue to be suffer from diabetes especially Black men. Although previous diabetes efforts have reduced overall disease burden, they have failed to eliminate racial and geographic disparities. The story of John Henry, the "steel-drivin' man" represents strength and self-determination among Black Men. But often these traits lead men to "manup" about their health and prevents them from taking care of their diabetes. This study examines how we can assist Black men in improving their diabetes. Based on the traits of John Henry, we will conduct a culturally-tailored study to 1) determine if our education program including coping strategies and motivation text messages lowers A1c; and, 2) how program operates in a rural setting while learning how we can best improve it for a larger study. We hope to have the information to conduct a larger study with Black men in rural areas to improve their diabetes outcomes.

Effectiveness

Safety

Semaglutidefor Diabetes Mellitus, Type 2

This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the

Effectiveness

Safety

MTM + ILIfor Diabetes Mellitus, Type 2

This study is evaluating whether a medically tailored meal + intensive lifestyle intervention can improve health outcomes for people with diabetes and food insecurity.

Effectiveness

Safety

Office Guidelines Applied To Practice (Office-GAP) + Mobile Text Messagingfor Diabetes Mellitus, Type 2

Cardiovascular disease (CVD) complications are the leading cause of diabetes mellitus (DM)-related morbidity and mortality, creating a significant burden on the public health system. This burden is, in part, attributable to poor medication adherence, with 21-42% of patients failing to properly adhere to their care. Importantly, this issue is especially pronounced in minority and low-income populations, which show higher rates of chronic illness and lower medication adherence. Interventions that foster and reinforce patient-centered communication between clinicians and patients show promise in improving health outcomes. However, they have not been widely implemented, in part due to a lack of compelling evidence for their effectiveness in primary care settings. Project Objective: The investigators propose to evaluate the impact of a patient activation program: Office Guidelines Applied to Practice (Office-GAP) combined with mobile text messaging reinforcement (Way to Health [W2H]) on medication adherence in patients with DM compared to mobile texting alone. Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. W2H is a texting service that informs and encourages patients to adhere to goals and improve communication. The long-term goal is to develop a model that can reliably improve and sustain adherence and can be successfully implemented in primary care clinics to close the morbidity and mortality gap for minority/low-income DM patients. The hypothesis is that the combined face-to-face patient activation and texting- delivered reinforcement methods will facilitate communication between patients and providers, improving the frequency, accuracy, and timeliness of communication while reinforcing shared goals and engendering mutual respect more than texting alone. Improved communication between patients and providers may improve medication adherence, blood sugar, cholesterol, blood pressure control, and patient satisfaction with providers, and ultimately decrease burden of illness. Research Strategy: The investigators will conduct a randomized community-based clinical trial in Federally-Qualified Health Centers (FQHCs) in Michigan enrolling 378 patients in 17 teams. All patients will receive usual care and medication for DM and CVD prevention. Eight teams will use W2H alone, and 9 teams will combine Office-GAP with WTH. The investigators will evaluate the impact of shared decision-making strategies for patients and providers. Impact: If successfully translated to clinical practice, these interventions have the potential to significantly impact patient care in FQHCs, improving outcomes for DM and CVD. This research also paves the way for shifting clinical practice across a spectrum of chronic disease where medication non-adherence is an issue.

Effectiveness

Safety

Allogeneic Adipose-derived Mesenchymal Stem Cells (MSC)-Single Infusionfor Kidney Diseases

This study is evaluating whether a type of white blood cell called mesenchymal stem cells may help treat chronic kidney disease.

Effectiveness

Safety

ORMD-0801 (Insulin) Capsule 8 Mg BDfor Diabetes Mellitus, Type 2

This study is evaluating whether a new insulin pill may help treat type 2 diabetes and NASH.

Effectiveness

Safety

Dexcom G6 Professional Continuous Glucose Monitorfor Premature Birth

This study is evaluating whether a set of activities can improve sleep habits in people with dementia.

Effectiveness

Safety

Ticagrelor Monotherapyfor Diabetes Mellitus

This study is evaluating whether a drug called ticagrelor may be able to help reduce the risk of heart attacks and strokes in patients with coronary artery disease.

Effectiveness

Safety

High Carbohydrate (glycogen Loading)for Diabetes Mellitus, Type 2

This study is evaluating whether glycogen content in the liver may play a role in regulating glucose production.

Effectiveness

Safety

Semaglutidefor Diabetes Mellitus, Type 2

This study is evaluating whether a medicine may help prevent vision loss in people with diabetes.

Effectiveness

Safety

High-Fruit Dietfor Diabetes Mellitus, Type 2

Diabetes costs the U.S. healthcare system more than any other disease, and nearly half of Americans will develop either diabetes or prediabetes in their lifetime. It is therefore critical to find new strategies to treat or reverse diabetes. One such approach is adopting a healthy diet, which can dramatically improve blood sugar levels in adults with type 2 diabetes and even induce diabetes remission. Despite this, not much is known about which food groups are most effective at improving blood sugar levels in patients with diabetes. Interestingly, of the various food groups that comprise the Mediterranean diet, epidemiologic data suggests that whole fruit may be one of the most efficacious at both preventing type 2 diabetes and improving blood sugar in patients with type 2 diabetes. However, few clinical trials have investigated the effects of whole fruit on blood sugar control. This study will therefore be the first to determine the effects of increasing whole fruit as a food group in type 2 diabetes patients. This supervised controlled feeding trial will test whether consuming a diet rich in whole fruit for 12 weeks can induce diabetes remission and can improve blood sugar, liver fat, and cardiovascular health in adults with type 2 diabetes. Thereafter, participants will be followed for up to one year. As a secondary aim, this study will also test whether consuming a large amount of fructose in whole food form negatively affects liver fat and cardiovascular health.

Effectiveness

Safety

Socially-Based Exercise Intervention For Older Adultsfor Sarcopenia

This study is evaluating whether a mobile application may help improve the health of older adults.

Effectiveness

Safety

18F-MK6240 Injectionfor Prediabetic State

This study is evaluating whether diabetes and glycemia are related to brain tau accumulation.

Effectiveness

Safety

Canagliflozin 300 Mgfor Diabetes Mellitus, Type 2

This study is evaluating whether a drug may help lower blood sugar levels in people with type 2 diabetes.

Effectiveness

Safety

Dapagliflozinfor Diabetes Mellitus, Type 2

This study is evaluating whether a drug used to treat type 2 diabetes may help reduce kidney damage in type 1 diabetes.

Effectiveness

Safety

Technology Intensifiedfor Diabetes Mellitus, Type 2

This study is evaluating whether a technology-based intervention can help people with diabetes.

Effectiveness

Safety

Avocado Vouchersfor Dietary Habits

Hispanic/Latino adults in the United States (U.S.) bear a disproportionate burden of type 2 diabetes (T2D). Dietary changes, facilitated by increased access and adherence to healthy foods, are necessary. In this study, continuous glucose monitoring (CGM) will be used to quantify changes in glycemic control in Hispanic/Latino (predominantly of Mexican origin) adults with or at-risk of T2D before and after receiving free avocados for 12 weeks. Beyond CGM-measured glycemic control, wearable activity and sleep monitors, physical exams, laboratory analyses, and questionnaires/logs will be used to track the impact of free avocado vouchers. The findings are anticipated to help clinicians provide new information to support positive behavior change to reduce the risk of T2D or progression from pre-diabetes to T2D and make it easier for patients to access healthier food, potentially leading to improved health.

Effectiveness

Safety

Hot Waterfor Diabetes Mellitus

Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM. This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.

Effectiveness

Safety

Use Of Patient Portal For Diabetes Managementfor Education, Patient

The purpose of the study is to develop and evaluate a multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).

Effectiveness

Safety

Semaglutidefor Diabetes Mellitus, Type 2

This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes. The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies. Participants will either get: Semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with NNC0480-0389 (a potential new medicine) or placebo (a 'dummy' medicine that looks like the medicines but without any medicine). NNC0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance. Participant will need to take 2-3 injections once every week during the study. One injection will be with semaglutide or placebo and 1-2 injections will be with NNC0480-0389 or placebo. Participant must inject the study medicines themself into the stomach, thigh, or upper arm. The study will last for about 41weeks. Participant will have 20 clinic visits. Participant will have blood samples taken at all clinic visits. At 3 clinic visits, participant will also have an electrocardiogram (ECG). This is a test to check participants heart. Participant will have their eyes checked before or at the start of the study and at the end of the study. Women can only take part in the study if they are not able to become pregnant

Effectiveness

Safety

Meal Replacement Shakefor Diabetes Mellitus

This is an open-label single-arm observational trial to study the effectiveness of a commercially available meal-replacement shake and its effect on the quality of life in individuals with type 2 diabetes.

Effectiveness

Safety

Goldenseal (Hydrastis Canadensis)for Diabetes Mellitus, Type 2

This study is evaluating whether goldenseal might interact with metformin in people with diabetes.

Effectiveness

Safety

CDS Tool Accessfor Diabetes Mellitus, Type 2

This study is evaluating whether providing care team members with clinical decision support tools can improve outcomes for patients with hypertension and diabetes.

Effectiveness

Safety

IcoSemafor Diabetes Mellitus

This study is evaluating whether a new medicine can control blood sugar levels in people with type 2 diabetes.

Diabetes Type 2 Clinical Trials 2022

Diabetes Type 2 studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect diabetes type 2 clinical trial in 2022.

Time-Restricted Eatingfor Feeding, Time Restricted

PHOENIXfor Diabetes Mellitus, Type 2

Diabetes Homeless Medication Support (D-Homes)for Psychological Distress

Empathy In Action For Life With Diabetes.for Diabetes Mellitus

Cagrilintide 2.4 Mgfor Diabetes Mellitus, Type 2

Fit 24for Diabetes Mellitus, Type 2

Shared Decision-making For Diabetes Preventionfor Diabetes, Gestational

Family Dyad Interventionfor Cardiovascular Diseases

Semaglutidefor Kidney Diseases

On-screen Electronic Alertfor Diabetes Mellitus, Type 2

Community Health Navigator Programfor Chronic Kidney Diseases

Community Health Navigator Programfor Chronic Kidney Diseases

Community Health Navigator Programfor Chronic Kidney Diseases

Diabetes Self-management Educationfor Diabetes Mellitus, Type 2

Phosphatidylserinefor Diabetes Mellitus

Standard Insulin Administration Educationfor Diabetes Mellitus, Type 2

Semaglutidefor Kidney Diseases

Budgeting, Purchasing And Cooking Educational Interventionfor Diabetes Mellitus, Type 2

Goodbelly Firstfor Diabetes Mellitus, Type 2

ENCOMPASS Interventionfor Chronic Kidney Diseases

Dulaglutidefor Diabetes Mellitus

Cecelia Health Plus OneTouch Verio Reflect® BGM And OneTouch Reveal® Mobile Appfor Diabetes Mellitus

Diabetes Self-management Coachingfor Diabetes Mellitus, Type 2

GZR-18for Diabetes Mellitus, Type 2

Semaglutide 1 Mgfor Diabetes Mellitus, Type 2

SomaSignal Informed Medical Management SSCVDfor Diabetes Mellitus

Normal Salinefor Diabetes Mellitus

Dapagliflozinfor Diabetes Mellitus

Insulin Detemirfor Diabetes, Gestational

Case-managementfor Diabetes Mellitus, Type 2

ELGfor Diabetes Mellitus

Afrezzafor Diabetes, Autoimmune

Zanamivirfor Diabetes Mellitus

Type 2 Diabetes Appropriate Food Boxes + Diabetes Educationfor Diabetes Mellitus, Type 2

MTMfor Diabetes Mellitus, Type 2

Healthy Food Subsidyfor Diabetes Mellitus, Type 2

Oral Semaglutidefor Diabetes Mellitus, Type 2

Insulin Icodecfor Diabetes Mellitus, Type 2

Family Diabetes Self-Management Education And Supportfor Diabetes Mellitus, Type 2

Ertugliflozin 5 Mgfor Diabetes Mellitus

Autologous Adipose-derived Mesenchymal Stem/stromal Cells (MSC) Higher Dosefor Diabetes Mellitus, Type 2

Tailored Lighting Interventionfor Alzheimer Disease

Peer Led Diabetes Self-Management Supportfor Diabetes Mellitus

IcoSemafor Diabetes Mellitus

Diabetes Educationfor Diabetes Mellitus

Tirzepatide Dose 2for Type2 Diabetes

Exogenous Ketone Monoesterfor Diabetes Mellitus

Noom Mobile Applicationfor Diabetes Mellitus

MANUPfor Coping Behavior

Semaglutidefor Diabetes Mellitus, Type 2

MTM + ILIfor Diabetes Mellitus, Type 2

Office Guidelines Applied To Practice (Office-GAP) + Mobile Text Messagingfor Diabetes Mellitus, Type 2

Allogeneic Adipose-derived Mesenchymal Stem Cells (MSC)-Single Infusionfor Kidney Diseases

ORMD-0801 (Insulin) Capsule 8 Mg BDfor Diabetes Mellitus, Type 2

Dexcom G6 Professional Continuous Glucose Monitorfor Premature Birth

Ticagrelor Monotherapyfor Diabetes Mellitus

High Carbohydrate (glycogen Loading)for Diabetes Mellitus, Type 2

Semaglutidefor Diabetes Mellitus, Type 2

High-Fruit Dietfor Diabetes Mellitus, Type 2

Socially-Based Exercise Intervention For Older Adultsfor Sarcopenia

18F-MK6240 Injectionfor Prediabetic State

Canagliflozin 300 Mgfor Diabetes Mellitus, Type 2

Dapagliflozinfor Diabetes Mellitus, Type 2

Technology Intensifiedfor Diabetes Mellitus, Type 2

Avocado Vouchersfor Dietary Habits

Hot Waterfor Diabetes Mellitus

Use Of Patient Portal For Diabetes Managementfor Education, Patient

Semaglutidefor Diabetes Mellitus, Type 2

Meal Replacement Shakefor Diabetes Mellitus

Goldenseal (Hydrastis Canadensis)for Diabetes Mellitus, Type 2

CDS Tool Accessfor Diabetes Mellitus, Type 2

IcoSemafor Diabetes Mellitus